Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOCLEAR L.A.-260 vs AEROLATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline causes bronchodilation by inhibiting phosphodiesterase, increasing c AMP levels, and antagonizing adenosine receptors.
Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD)
FDA-approved: Treatment of asthma and chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity, bradycardia in preterm infants
Theophylline (THEOCLEAR L. A.-260) 260 mg orally every 12 hours. Adjust dose based on serum theophylline concentrations to achieve 5-15 mcg/m L.
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
Terminal elimination half-life is approximately 6-12 hours in adults (range 3-12 hours, prolonged in congestive heart failure, liver disease, and with certain drugs). In neonates, half-life is prolonged (24-36 hours).
Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days
Hepatic via CYP1A2, CYP2E1, and CYP3A4; undergoes N-demethylation and oxidation.
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by xanthine oxidase and N-acetyltransferase. Metabolites excreted renally.
Renal elimination of unchanged drug (10%) and hepatic metabolism (90%). Metabolism is primarily via CYP1A2 and CYP3A4, with metabolites excreted in urine (about 80% of the dose) and feces (about 20%).
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other
Approximately 40% bound to plasma proteins, primarily albumin.
65% bound to albumin
Volume of distribution: 0.4-0.5 L/kg, indicating distribution into total body water. Higher Vd in neonates and patients with obesity.
2.5 L/kg (extensive tissue distribution, suggests high lung penetration)
Oral bioavailability: 96% to 100% for immediate-release formulations; sustained-release formulations have similar bioavailability but with prolonged absorption.
Oral: 40% (first-pass metabolism); Inhaled: 20% (lung deposition)
No specific GFR-based dose adjustment recommended; however, monitor serum levels closely in renal impairment (Cr Cl <30 m L/min) due to potential accumulation of metabolites.
No dose adjustment required for renal impairment. Drug is primarily hepatically metabolized and renally excreted as inactive metabolites; however, significant accumulation is not expected in renal dysfunction.
Avoid use in Child-Pugh class C; for Child-Pugh class A or B, reduce dose by 50% and monitor serum concentrations.
Child-Pugh Class A: No dose adjustment. Class B: Reduce dose to 50% of normal, monitor for adverse effects. Class C: Use with caution; reduce dose to 25-50% and monitor closely. Specific data for AEROLATE limited; adjust based on clinical response and tolerance.
Children 6 months-9 years: Starting dose 12-14 mg/kg/day orally divided every 4-6 hours (immediate-release) or every 12 hours (sustained-release). Children 9-16 years: 12-14 mg/kg/day (max 900 mg/day) divided every 6-8 hours (immediate-release) or every 12 hours (sustained-release). Adjust to serum level 5-15 mcg/m L.
Children 4-11 years: 1-2 inhalations (90 mcg each) twice daily; maximum 2 inhalations twice daily. Children 12 years and older: Same as adult dosing. Administer via inhaler with spacer for optimal delivery. Weight-based dosing not typically used; fixed doses per age group.
Elderly patients (≥60 years): Start at 300 mg/day orally (sustained-release) in divided doses every 12 hours; titrate slowly, monitor serum levels, as clearance is reduced.
No specific dose adjustment required. Use lowest effective dose due to potential for increased systemic exposure from reduced clearance and higher risk of adverse effects (e.g., osteoporosis, hyperglycemia). Monitor for cardiac effects and adrenal suppression.
No FDA black box warning.
No FDA black box warning.
Monitor serum theophylline levels to avoid toxicity; use with caution in patients with cardiac disease, seizure disorders, hepatic impairment, or COPD exacerbation; may interact with multiple drugs altering clearance.
Monitor serum theophylline levels due to narrow therapeutic index (10-20 mcg/m L).,Risk of toxicity at high levels: seizures, arrhythmias, death.,Use with caution in patients with hepatic impairment, heart failure, fever, or elderly.,Cigarette smoking and certain drugs (e.g., rifampin, phenytoin) induce metabolism; others (e.g., cimetidine, macrolides) inhibit metabolism.
Hypersensitivity to theophylline or any component; active seizure disorder not controlled by therapy.
Hypersensitivity to theophylline or any component.,Active peptic ulcer disease.,Uncontrolled seizure disorders.
Avoid excessive intake of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may potentiate theophylline's CNS stimulant effects and toxicity. Concurrent ingestion of charcoal-broiled meats may increase theophylline clearance, potentially reducing efficacy. Grapefruit juice has been reported to increase theophylline levels; limit intake. A high-protein diet may increase clearance; maintain consistent dietary habits.
Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may potentiate CNS stimulation and toxicity. Food does not significantly affect absorption, but high-fat meals may delay absorption. Consistent dietary habits are recommended.
Theophylline is not a major teratogen. First trimester: No increased risk of major malformations based on population data. Second and third trimesters: Use may be associated with transient neonatal toxemia (e.g., jitteriness, tachycardia, vomiting) if maternal levels are high near term. Risk of respiratory distress syndrome or neonatal apnea is theoretical only.
AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theophylline crosses the placenta and can cause fetal tachycardia, jitteriness, and irritability; apneic episodes and respiratory failure reported in neonates exposed near term. Risk of preterm labor and low birth weight associated with maternal asthma exacerbation.
Theophylline is excreted into breast milk (M/P ratio approximately 0.6-0.7). Mean milk concentration is about 60-70% of maternal plasma. Relative infant dose is ~10% of maternal weight-adjusted dose. May cause irritability or insomnia in nursing infants, especially at high maternal doses. Benefits likely outweigh risks for asthma therapy, but monitor infant for signs of theophylline toxicity.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Peak milk levels occur 1-2 hours after maternal dosing. Estimated infant dose is about 1-10% of maternal weight-adjusted dose. Caution: irritability and jitteriness reported in breastfed infants. Avoid breastfeeding if maternal serum theophylline levels exceed 20 mcg/m L.
Pregnancy decreases theophylline clearance by 20-40% (especially third trimester). Dose may need reduction by 30-50% to maintain therapeutic levels, with close serum monitoring and adjustment every 2-4 weeks as pregnancy progresses. Smoking cessation (common in pregnancy) further reduces clearance and necessitates dose reduction.
Pregnancy may increase theophylline clearance (especially in second and third trimesters) due to increased renal perfusion and hepatic metabolism. Dose adjustments often required to maintain therapeutic levels. Initiate at standard dose and titrate based on serum levels and clinical response. Postpartum clearance decreases rapidly; doses should be reduced to pre-pregnancy levels within 2-4 weeks after delivery.
Theo-24 (theophylline extended-release) has a narrow therapeutic index (5-15 mcg/m L). Monitor serum levels due to significant interindividual variability in clearance. Avoid in patients with active peptic ulcer disease or seizure disorders unless absolutely necessary. Cimetidine, ciprofloxacin, and macrolides increase levels; smoking and rifampin decrease levels. Use with caution in heart failure, hepatic impairment, and elderly due to reduced clearance. For acute exacerbations, consider short-acting beta-agonists first.
AEROLATE (theophylline) has a narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders unless essential. Caution with hepatic impairment, heart failure, and in elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides, and CYP1A2 inhibitors increase levels; smoking and rifampin decrease levels.
Take exactly as prescribed, do not crush or chew extended-release tablets.,Avoid sudden discontinuation; may require tapering.,Report symptoms of toxicity: nausea, vomiting, insomnia, jitteriness, palpitations, or seizures.,Limit caffeine intake (coffee, tea, cola, chocolate) as it may increase side effects.,Discuss all medications with your doctor, especially antibiotics and heartburn drugs (cimetidine, ciprofloxacin).,Do not smoke; smoking increases metabolism and may require dose adjustments.,If you miss a dose, take it as soon as remembered unless close to next dose; do not double up.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without informing your doctor, as smoking affects the drug's metabolism.,Keep a list of all medications you take, including over-the-counter drugs and herbal supplements.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOCLEAR L.A.-260 vs AEROLATE, answered by our medical review team.
THEOCLEAR L.A.-260 is a Bronchodilator that works by Theophylline causes bronchodilation by inhibiting phosphodiesterase, increasing c AMP levels, and antagonizing adenosine receptors.. AEROLATE is a Bronchodilator that works by Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOCLEAR L.A.-260 and AEROLATE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOCLEAR L.A.-260 is: Theophylline (THEOCLEAR L. A.-260) 260 mg orally every 12 hours. Adjust dose based on serum theophylline concentrations to achieve 5-15 mcg/m L.. The standard adult dose of AEROLATE is: For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOCLEAR L.A.-260 and AEROLATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOCLEAR L.A.-260 is classified as Category C. Theophylline is not a major teratogen. First trimester: No increased risk of major malformations based on population data. Second and third trimesters: Use may be associated with t. AEROLATE is classified as Category C. AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.